|
1
|
Ren Z, Zhou S, Liu Z and Xu S: Randomized
controlled trials of induction treatment and surgery versus
combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: A
systematic review and meta-analysis. J Thorac Dis. 7:1414–1422.
2015.PubMed/NCBI
|
|
2
|
Tsim S, O'Dowd CA, Milroy R and Davidson
S: Staging of non-small cell lung cancer (NSCLC): A review. Respir
Med. 104:1767–1774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang Y, Xie Y and Xian L: Breast cancer
susceptibility gene 1 (BRCA1) predict clinical outcome in platinum-
and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC)
patients: A system review and meta-analysis. J Exp Clin Cancer Res.
32:152013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Detterbeck FC, Chansky K, Groome P,
Bolejack V, Crowley J, Shemanski L, Kennedy C, Krasnik M, Peake M
and Rami-Porta R; IASLC Staging and Prognostic Factors Committee,
Advisory Boards, and Participating Institutions: The IASLC lung
cancer staging project: Methodology and validation used in the
development of proposals for revision of the stage classification
of NSCLC in the forthcoming (Eighth) edition of the TNM
classification of lung cancer. J Thorac Oncol. 11:1433–1446. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Santiago A, Barczyk S, Jelen U,
Engenhart-Cabillic R and Wittig A: Challenges in radiobiological
modeling: can we decide between LQ and LQ-L models based on
reviewed clinical NSCLC treatment outcome data? Radiat Oncol.
11:672016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gelsomino F, Ambrosini V, Melotti B,
Sperandi F and Ardizzoni A: Pitfalls in oncology: Osteoblastic
response mimicking bone progression during ceritinib treatment in
ALK-rearranged NSCLC. J Thorac Oncol. 11:e99–e101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bronte G, Passiglia F, Galvano A and Russo
A: Anti-angiogenic drugs for second-line treatment of NSCLC
patients: Just new pawns on the chessboard? Expert Opin Biol Ther.
16:1–5. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xie FJ, Lu HY, Zheng QQ, Qin J, Gao Y,
Zhang YP, Hu X and Mao WM: The clinical pathological
characteristics and prognosis of FGFR1 gene amplification in
non-small-cell lung cancer: A meta-analysis. Onco Targets Ther.
9:171–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moro-Sibilot D, Smit E, de Castro Carpeño
J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine
K, Dyachkova Y, Smith KT, et al: Non-small cell lung cancer
patients with brain metastases treated with first-line
platinum-doublet chemotherapy: Analysis from the European FRAME
study. Lung Cancer. 90:427–432. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lim SH, Sun JM, Lee SH, Ahn JS, Park K and
Ahn MJ: Pembrolizumab for the treatment of non-small cell lung
cancer. Expert Opin Biol Ther. 16:397–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calabuig-Fariñas S, Lewintre EJ,
Mayo-De-Las-Casas C, Cordellat AB, Molina-Vila MA, Rosell R and
Camps C: 149P: The role of CTCs and cfDNA for diagnosis and
monitoring of EGFR mutations in advanced NSCLC patients. J Thorac
Oncol. 11(4 Suppl): S1232016. View Article : Google Scholar
|
|
12
|
Mascalchi M, Falchini M, Maddau C,
Salvianti F, Nistri M, Bertelli E, Sali L, Zuccherelli S, Vella A,
Matucci M, et al: Prevalence and number of circulating tumour cells
and microemboli at diagnosis of advanced NSCLC. J Cancer Res Clin
Oncol. 142:195–200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koh MS, Tee A, Wong P, Antippa P and
Irving LB: Advances in lung cancer diagnosis and staging:
endobronchial ultrasound. Intern Med J. 38:85–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuo CH, Lin SM, Chen HC, Chou CL, Yu CT
and Kuo HP: Diagnosis of peripheral lung cancer with three echoic
features via endobronchial ultrasound. Chest. 132:922–929. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ernst A, Feller-Kopman D and Herth FJ:
Endobronchial ultrasound in the diagnosis and staging of lung
cancer and other thoracic tumors. Semin Thorac Cardiovasc Surg.
19:201–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Loria F, Loria G, Basile S, Crea G,
Randazzo D and Frosina L: Contrast-enhanced ultrasound of
hepatocellular carcinoma: correlation between enhancement pattern
and cellular differentiation on histopathlogy. Updates Surg.
64:247–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu H, Jiang Y, Dai Q, Zhu Q, Wang L and
Lu J: Peripheral enhancement of breast cancers on contrast-enhanced
ultrasound: Correlation with microvessel density and vascular
endothelial growth factor expression. Ultrasound Med Biol.
40:293–299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duguay S, Wagner JM, Zheng W, Ling J, Zhao
LC, Allen KS, North JC and Deb SJ: Ultrasound-guided needle biopsy
of neck lymph nodes in patients with suspected lung cancer: Are the
specimens sufficient for complete pathologic evaluation to guide
patient management? Ultrasound Q. 33:133–138. 2016. View Article : Google Scholar
|
|
19
|
Castro-Pocas FM, Araüjo TP, Ferreira ML
and Saraiva MM: The role of endoscopic ultrasound in a case of lung
cancer with jaundice. Endosc Ultrasound. Nov 8. 2016, (Epub ahead
of print). PubMed/NCBI
|
|
20
|
Loriot Y, Mordant P, Dorvault N, de la
motte Rouge T, Bourhis J, Soria JC and Deutsch E: BMS-690514, a
VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural
activity on non-small-cell lung cancer xenografts and induces
sequence-dependent synergistic effect with radiation. Br J Cancer.
103:347–353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Donnem T, Al-Shibli K, Al-Saad S,
Delghandi MP, Busund LT and Bremnes RM: VEGF-A and VEGFR-3
correlate with nodal status in operable non-small cell lung cancer:
Inverse correlation between expression in tumor and stromal cels.
Lung Cancer. 63:277–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Szturmowicz M, Rudzinski P, Kacprzak A,
Langfort R, Bestry I, Broniarek-Samson B and Orłowski T: Prognostic
value of serum C-reactive protein (CRP) and cytokeratin 19
fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in
surgically treated patients with non-small cell lung cancer.
Pneumonol Alergol Pol. 82:422–429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dai H, Liu J, Liang L, Ban C, Jiang J, Liu
Y, Ye Q and Wang C: Increased lung cancer risk in patients with
interstitial lung disease and elevated CEA and CA125 serum tumour
markers. Respirology. 19:707–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xing W, Zhigang W, Bing H, Haitao R, Pan
L, Chuanshan X, Yuanyi Z and Ao L: Targeting an ultrasound contrast
agent to folate receptors on ovarian cancer cells: Feasibility
research for ultrasonic molecular imaging of tumor cels. J
Ultrasound Med. 29:609–614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vansteenkiste J, de Ruysscher D, Eberhardt
WE, Lim E, Senan S, Felip E and Peters S; ESMO Guidelines Working
Group: Early and locally advanced non-small-cell lung cancer
(NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 24(Suppl 6): vi89–vi98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schinkel AF, Kaspar M and Staub D:
Contrast-enhanced ultrasound: Clinical applications in patients
with atherosclerosis. Int J Cardiovasc Imaging. 32:35–48. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen CL, Hu GY, Mei Q, Qiu H, Long GX and
Hu GQ: Epidermal growth factor receptor-targeted ultra-small
superparamagnetic iron oxide particles for magnetic resonance
molecular imaging of lung cancer cells in vitro. Chin Med J (Engl).
125:2322–2328. 2012.PubMed/NCBI
|
|
29
|
Sutiman N, Tan SW, Tan EH, Lim WT,
Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK and Chowbay B:
EGFR mutation subtypes influence survival outcomes following
first-line gefitinib therapy in advanced Asian NSCLC patients. J
Thorac Oncol. 12:529–538. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou JG, Tian X, Wang X, Tian JH, Wang Y,
Wang F, Zhang Y and Ma H: Treatment on advanced NSCLC:
Platinum-based chemotherapy plus erlotinib or platinum-based
chemotherapy alone? A systematic review and meta-analysis of
randomised controlled trials. Med Oncol. 32:4712015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Angelov KG, Vasileva MB, Grozdev KS,
Sokolov MB and Todorov G: Clinical and pathological
characteristics, and prognostic factors for gastric cancer survival
in 155 patients in Bulgaria. Hepatogastroenterology. 61:2421–2444.
2014.PubMed/NCBI
|
|
32
|
Granja RH, Salerno AG, de Lima AC,
Montalvo C, Reche KV, Giannotti FM and Wanschel AC: Liquid
chromatography/tandem mass spectrometry method to determine
boldenone in bovine liver tissues. J AOAC Int. 97:1476–1480.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kong Y, Wang P, Liu S, Zhao G and Peng Y:
SEM analysis of the interfacial transition zone between
cement-glass powder paste and aggregate of mortar under microwave
curing. Materials (Basel). 9:pii: E7332016. View Article : Google Scholar
|
|
34
|
Gainor JF, Tan DS, de Pas T, Solomon BJ,
Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet
L, et al: Progression-free and overall survival in ALK-Positive
NSCLC patients treated with sequential crizotinib and ceritinib.
Clin Cancer Res. 21:2745–2752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Magnuson WJ, Yeung JT, Guillod PD,
Gettinger SN, Yu JB and Chiang VL: Impact of deferring radiation
therapy in patients with epidermal growth factor receptor-mutant
non-small cell lung cancer who develop brain metastases. Int J
Radiat Oncol Biol Phys. 95:673–679. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thill PG, Goswami P, Berchem G and Domon
B: Lung cancer statistics in Luxembourg from 1981 to 2008. Bull Soc
Sci Med Grand Duche Luxemb. 2:43–55. 2011.
|
|
37
|
Reck M, Popat S, Reinmuth N, de Ruysscher
D, Kerr KM and Peters S; ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25(Suppl 3): iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang S, Nan Y, Tian Y, Zhang W, Zhou B, Bu
L, Huo S, Chen G, Yu J and Zheng S: Study of distinct protein
profiles for early diagnosis of NSCLC using LCM and SELDI-TOF-MS.
Med Oncol. 25:380–386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vázquez-Sequeiros E,
González-Panizo-Tamargo F, Barturen Á, Calderón Á, Esteban JM,
Fernández-Esparrach G, Gimeno-García A, Ginés A, Lariño J,
Pérez-Carreras M, et al: The role of endoscopic ultrasound guided
fine needle aspiration (EUS-FNA) in non small cell lung cancer
(NSCLC) patients: SEED-SEPD-AEG joint guideline. Rev Esp Enferm
Dig. 105:215–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pennell NA and Lynch TJ Jr: Combined
inhibition of the VEGFR and EGFR signaling pathways in the
treatment of NSCLC. Oncologist. 14:399–411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Y, Guessous F, Kofman A, Schiff D
and Abounader R: XL-184, a MET, VEGFR-2 and RET kinase inhibitor
for the treatment of thyroid cancer, glioblastoma multiforme and
NSCLC. IDrugs. 13:112–121. 2010.PubMed/NCBI
|
|
42
|
Ishikawa H, Satoh H, Yamashita YT, Ohtsuka
M and Sekizawa K: CEA and survival in patients with stage IA-B
NSCLC. Thorac Cardiovasc Surg. 50:2532002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cedrés S, Nuñez I, Longo M, Martinez P,
Checa E, Torrejón D and Felip E: Serum tumor markers CEA,
CYFRA21-1, and CA-125 are associated with worse prognosis in
advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer.
12:172–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fiala O, Pesek M, Finek J, Benesova L,
Minarik M, Bortlicek Z and Topolcan O: Predictive role of CEA and
CYFRA 21-1 in patients with advanced-stage NSCLC treated with
erlotinib. Anticancer Res. 34:3205–3210. 2014.PubMed/NCBI
|
|
45
|
Chen F, Wang XY, Han XH, Wang H and Qi J:
Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of
early-stage NSCLC from benign lung disease. Int J Clin Exp Med.
8:11295–11300. 2015.PubMed/NCBI
|
|
46
|
Kallmayer M, Tsantilas P, Zieger C, Ahmed
A, Söllner H, Zimmermann A and Eckstein H: Ultrasound surveillance
after CAS and CEA: What's the evidence? J Cardiovasc Surg (Torino).
55(2 Suppl 1): S33–S41. 2014.
|
|
47
|
Ignee A, Schuessler G, Cui XW and Dietrich
CF: Intracavitary contrast medium ultrasound-different
applications, a review of the literature ad future prospects.
Ultraschall Med. 34:504–525; quiz 526–528. 2013.(In German).
PubMed/NCBI
|
|
48
|
Lee SH, Kim JM, Chan V, Kim HJ and Kim HI:
Ultrasound-guided cervical periradicular steroid injection for
cervical radicular pain: Relevance of spread pattern and degree of
penetration of contrast medium. Pain Med. 14:5–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
de Ziegler D: Contrast ultrasound: A
simple-to-use phase-shifting medium offers saline infusion
sonography-like images. Fertil Steril. 92:369–373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang S, Yang W, Fu JJ, Sun Y, Zhang H, Bai
J, Chen MH and Yan K: Microflow imaging of contrast-enhanced
ultrasound for evaluation of neovascularization in peripheral lung
cancer. Medicine (Baltimore). 95:e43612016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chopra A: 125I-Labeled
heparin-binding peptides that target heparan sulfate proteoglycans
for the in vivo imaging of peripheral amyloidosis. Molecular
Imaging and Contrast Agent Database (MICAD) [Internet]. National
Center for Biotechnology Information (US); Bethesda, MD; 2011
|
